Current Research in Translational Medicine最新文献

{"title":"Role of next-generation sequencing in acquired amegakaryocytic thrombocytopenic purpura","authors":"Lorenzo Lazzari , Lucia Bongiovanni , Paola Ronchi , Gregorio Maria Bergonzi , Camilla Gariazzo , Elisa Diral , Fabio Ciceri , Andrea D'Alessio , Maurilio Ponzoni","doi":"10.1016/j.retram.2024.103441","DOIUrl":"10.1016/j.retram.2024.103441","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 1","pages":"Article 103441"},"PeriodicalIF":4.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139590521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of chimeric antigen receptor therapy beyond oncology: A bibliometric and visualized analysis","authors":"Linxin Yang ,&nbsp;Jinshen He ,&nbsp;Jiahao Liu ,&nbsp;Tianjian Xie ,&nbsp;Qi Tang","doi":"10.1016/j.retram.2024.103442","DOIUrl":"10.1016/j.retram.2024.103442","url":null,"abstract":"<div><h3>Purpose</h3><p>Chimeric antigen receptor therapy beyond oncology has gained increasing attention. While a substantial number of publications have emerged in recent years, there has been a paucity of conducted bibliometric studies. Our objective is to systematically summarize and visually analyze the literature in the field of chimeric antigen receptors therapy beyond oncology and explore hotspots in this field.</p></div><div><h3>Methods</h3><p>Web of Science Core Collection was selected as the data source, and the data was retrieved on December 23, 2022, according to the search strategy. CiteSpace 6.1.R6 and Vosviewer 1.6.18 were used to analyze publications and explore research hotspots and directions.</p></div><div><h3>Results</h3><p>A total of 338 publications written by 1832 authors from 516 institutions in 42 countries/regions were selected for the analysis. The number of publications is steadily increasing annually. The United States emerged as the primary contributor, and University of Pennsylvania was the leading institution. Frontiers in Immunology boasted the highest number of published papers. Kitchen SG, Riley JL, and Scott DW were the most productive researchers in this field. The keyword cluster analysis identified HIV, autoimmune diseases, transplant related diseases and COVID-19 as the primary focus areas within the realm of chimeric antigen receptor therapy beyond oncology.</p></div><div><h3>Conclusion</h3><p>The advancement of chimeric antigen receptor therapy beyond oncology has witnessed rapid progress in recent years. We have explored the hotspots and research directions in this field. It is hoped that this study could provide references and directions for future clinical researches.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 3","pages":"Article 103442"},"PeriodicalIF":4.1,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139769994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical applications of immunosequencing","authors":"B. Bardwell ,&nbsp;J. Bay ,&nbsp;Z. Colburn","doi":"10.1016/j.retram.2024.103439","DOIUrl":"10.1016/j.retram.2024.103439","url":null,"abstract":"<div><p>Technological advances in high-throughput sequencing have opened the door for the interrogation of adaptive immune responses at unprecedented scale. It is now possible to determine the sequences of antibodies or T-cell receptors produced by individual B and T cells in a sample. This capability, termed immunosequencing, has transformed the study of both infectious and non-infectious diseases by allowing the tracking of dynamic changes in B and T cell clonal populations over time. This has improved our understanding of the pathology of cancers, autoimmune diseases, and infectious diseases. However, to date there has been only limited clinical adoption of the technology. Advances over the last decade and on the horizon that reduce costs and improve interpretability could enable widespread clinical use. Many clinical applications have been proposed and, while most are still undergoing research and development, some methods relying on immunosequencing data have been implemented, the most widespread of which is the detection of measurable residual disease. Here, we review the diagnostic, prognostic, and therapeutic applications of immunosequencing for both infectious and non-infectious diseases.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 3","pages":"Article 103439"},"PeriodicalIF":4.1,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139461405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytogenetics in the management of hematological malignancies: An overview of alternative technologies for cytogenetic characterization","authors":"Valentin Lestringant ,&nbsp;Hélène Guermouche-Flament ,&nbsp;Mélanie Jimenez-Pocquet ,&nbsp;Jean-Baptiste Gaillard ,&nbsp;Dominique Penther","doi":"10.1016/j.retram.2024.103440","DOIUrl":"10.1016/j.retram.2024.103440","url":null,"abstract":"<div><p>Genomic characterization is an essential part of the clinical management of hematological malignancies for diagnostic, prognostic and therapeutic purposes. Although CBA and FISH are still the gold standard in hematology for the detection of CNA and SV, some alternative technologies are intended to complement their deficiencies or even replace them in the more or less near future. In this article, we provide a technological overview of these alternatives. CMA is the historical and well established technique for the high-resolution detection of CNA. For SV detection, there are emerging techniques based on the study of chromatin conformation and more established ones such as RTMLPA for the detection of fusion transcripts and RNA-seq to reveal the molecular consequences of SV. Comprehensive techniques that detect both CNA and SV are the most interesting because they provide all the information in a single examination. Among these, OGM is a promising emerging higher-solution technique that offers a complete solution at a contained cost, at the expense of a relatively low throughput per machine. WGS remains the most adaptable solution, with long-read approaches enabling very high-resolution detection of CAs, but requiring a heavy bioinformatics installation and at a still high cost. However, the development of high-resolution genome-wide detection techniques for CAs allows for a much better description of chromoanagenesis. Therefore, we have included in this review an update on the various existing mechanisms and their consequences and implications, especially prognostic, in hematological malignancies.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 3","pages":"Article 103440"},"PeriodicalIF":4.1,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452318624000035/pdfft?md5=e7561bfa72b241b6f1f7d35dd90d8c94&pid=1-s2.0-S2452318624000035-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139475391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Luspatercept for the treatment of congenital sideroblastic anemia: Two case reports","authors":"Yuanyuan Shao,&nbsp;Li He,&nbsp;Shaoxue Ding,&nbsp;Rong Fu","doi":"10.1016/j.retram.2024.103438","DOIUrl":"10.1016/j.retram.2024.103438","url":null,"abstract":"<div><p><span>Congenital sideroblastic anemia<span> (CSA) is a group of disorders caused by different genetic mutations that result in low iron utilization and ineffective erythropoiesis<span><span>. Current treatments are limited, and some patients do not respond to </span>vitamin B6<span> therapy. Luspatercept is a novel erythropoietic maturation agent approved for adult β-thalassemia and Myelodysplastic syndromes with ring sideroblasts (MDS-RS) associated with ineffective erythropoiesis. Here we report 2 patients with CSA due to mutations in </span></span></span></span><em>ALAS2</em> and <em>SLC25A38</em><span> genes who became unresponsive after a period of treatment with vitamin B6 and iron chelators but achieved transfusion independence and a markedly reduced spleen after combination with luspatercept.</span></p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 1","pages":"Article 103438"},"PeriodicalIF":4.1,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139461442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autologous intraarterial pancreatic bone-marrow mononuclear cells infusion in T2D patients: Changes on beta-cells function, insulin resistance, and inflammatory marker","authors":"Farid Kurniawan ,&nbsp;Imam Subekti ,&nbsp;Em Yunir ,&nbsp;Dante Saksono Harbuwono ,&nbsp;Dyah Purnamasari ,&nbsp;Tri Juli Edi Tarigan ,&nbsp;Wismandari Wisnu ,&nbsp;Dicky Levenus Tahapary ,&nbsp;Syahidatul Wafa ,&nbsp;Cindy Astrella ,&nbsp;Eunike Vania Christabel ,&nbsp;Anna Mira Lubis ,&nbsp;Ika Prasetya Wijaya ,&nbsp;Birry Karim ,&nbsp;Mohamad Syahrir Azizi ,&nbsp;Indrati Suroyo ,&nbsp;Sahat Matondang ,&nbsp;Krishna Pandu Wicaksono ,&nbsp;Dewi Wulandari ,&nbsp;Iqbal Fasha ,&nbsp;Pradana Soewondo","doi":"10.1016/j.retram.2023.103437","DOIUrl":"10.1016/j.retram.2023.103437","url":null,"abstract":"<div><h3>Background</h3><p>Type 2 diabetes (T2D) is a progressive disease. Many drugs<span> currently being used for the management of T2D have minimal effect on pancreatic beta cells regeneration. Cell-based therapies might provide potential benefits in this aspect.</span></p></div><div><h3>Methods</h3><p>A pilot study in five T2D patients with 12 months follow-up was performed to evaluate the effect of autologous bone marrow mononuclear stem cells (BM-MNCs) infusion into pancreatic arteries on the insulin requirement, beta-cell function, insulin resistance, and systemic inflammatory marker (CRP).</p></div><div><h3>Results</h3><p>The primary endpoint, a 50 % reduction of total insulin doses from baseline, was not achieved in this study. However, a trend of increasing fasting C-peptide (<em>p</em> = 0.07) and C-peptide 60′ (<em>p</em> = 0.07) and 90′ (<em>p</em><span> = 0.07) after a mixed-meal tolerance test was observed 12 months post-infusion compared to baseline levels. A similar result was observed for the homeostatic model assessment of beta cell function (HOMA1-B), an index for beta cell function. No improvement was observed for insulin resistance measured by homeostasis model assessment of insulin resistance (HOMA1-IR) and systemic inflammatory parameter.</span></p></div><div><h3>Conclusion</h3><p>Intraarterial pancreatic autologous BM-MNCs infusion might potentially improve beta cell function in T2D patients, although further study is needed to confirm this finding.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 2","pages":"Article 103437"},"PeriodicalIF":4.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139068872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overlapping features of hepatic complications after hematopoietic cell transplantation in a rare T-cell lymphoma: A clinical challenge","authors":"Andrea Nunzi ,&nbsp;Giulia Ciangola ,&nbsp;Ilaria Cerroni ,&nbsp;Valeria Mezzanotte ,&nbsp;Gentiana Elena Trotta ,&nbsp;Federico Meconi ,&nbsp;Annagiulia Zizzari ,&nbsp;Vito Mario Rapisarda ,&nbsp;Luca Savino ,&nbsp;Arianna Brega ,&nbsp;Renato Argirò ,&nbsp;Gottardo De Angelis ,&nbsp;Benedetta Mariotti ,&nbsp;Fabrizio Bonanni ,&nbsp;Elisa Meddi ,&nbsp;Carmelo Gurnari ,&nbsp;Antoine Bruno ,&nbsp;Ilaria Mangione ,&nbsp;Adriano Venditti ,&nbsp;Raffaella Cerretti","doi":"10.1016/j.retram.2023.103436","DOIUrl":"10.1016/j.retram.2023.103436","url":null,"abstract":"<div><p>We present the case of a young adult, who developed several hepatic post-HCT complications, which made differential diagnosis extremely difficult.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 2","pages":"Article 103436"},"PeriodicalIF":4.1,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138816449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Catechol-O-methyltransferase gene (COMT) is associated with neurocognitive functioning in patients with sickle cell disease","authors":"Andrew M. Heitzer ,&nbsp;Sara R. Rashkin ,&nbsp;Ana Trpchevska ,&nbsp;Jennifer N. Longoria ,&nbsp;Evadnie Rampersaud ,&nbsp;Yunusa Olufadi ,&nbsp;Winfred C. Wang ,&nbsp;Darcy Raches ,&nbsp;Brian Potter ,&nbsp;Martin H Steinberg ,&nbsp;Allison A. King ,&nbsp;Guolian Kang ,&nbsp;Clifford M. Takemoto ,&nbsp;Jane S. Hankins","doi":"10.1016/j.retram.2023.103433","DOIUrl":"10.1016/j.retram.2023.103433","url":null,"abstract":"<div><h3>Purpose</h3><p><span><span>Neurocognitive impairment is a common and debilitating complication of sickle cell disease (SCD) resulting from a combination of biological and </span>environmental factors. The catechol-O-methyltransferase (</span><em>COMT</em><span><span>) gene modulates levels of dopamine availability in the prefrontal cortex. COMT has repeatedly been implicated in the perception of pain stimuli and frequency of pain crises </span>in patients with SCD and is known to be associated with neurocognitive functioning in the general population. The current study aimed to examine the associations of genetic variants in </span><em>COMT</em> and neurocognitive functioning in patients with SCD.</p></div><div><h3>Patients and Methods</h3><p><span>The Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort was used as a discovery cohort (</span><em>n</em> = 166). The genotypes for 5 SNPs (rs6269, rs4633, rs4818, rs4680, and rs165599) in <em>COMT</em><span> were extracted from whole genome sequencing data and analyzed using a dominant model. A polygenic score for </span><em>COMT</em> (PGS^COMT) integrating these 5 SNPs was analyzed as a continuous variable. The Cooperative Study of Sickle Cell Disease (CSSCD, <em>n</em><span> = 156) and the Silent Cerebral Infarction Transfusion (SIT, </span><em>n</em> = 114) Trial were used as 2 independent replication cohorts. Due to previously reported sex differences, all analyses were conducted separately in males and females. The Benjamini and Hochberg approach was used to calculate false discovery rate adjusted p-value (q-value).</p></div><div><h3>Results</h3><p>In SCCRIP, 1 out of 5 SNPs (rs165599) was associated with IQ at <em>q</em>&lt;0.05 in males but not females, and 2 other SNPs (rs4633 and rs4680) were marginally associated with sustained attention at <em>p</em>&lt;0.05 in males only but did not maintain at <em>q</em>&lt;0.05. PGS<em>^COMT</em> was negatively associated with IQ and sustained attention at <em>p</em>&lt;0.05 in males only. Using 3 cohorts’ data, 4 out of 5 SNPs (rs6269, rs4633, rs4680, rs165599) were associated with IQ (minimum q-value = 0.0036) at <em>q</em>&lt;0.05 among male participants but not female participants. The PGS<em>^COMT</em> was negatively associated with IQ performance among males but not females across all cohorts.</p></div><div><h3>Conclusion</h3><p>Select <em>COMT</em> SNPs are associated with neurocognitive abilities in males with SCD. By identifying genetic predictors of neurocognitive performance in SCD, it may be possible to risk-stratify patients from a young age to guide implementation of early interventions.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 2","pages":"Article 103433"},"PeriodicalIF":4.1,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138509177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjusting diffusing capacity for anemia in patients undergoing allogeneic HCT: a comparison of two methodologies","authors":"Hemang Yadav ,&nbsp;Mehrdad Hefazi Torghabeh ,&nbsp;Sumedh S Hoskote ,&nbsp;Kelly M Pennington ,&nbsp;Kaiser G Lim ,&nbsp;Paul D Scanlon ,&nbsp;Alexander S Niven ,&nbsp;William J Hogan","doi":"10.1016/j.retram.2023.103432","DOIUrl":"10.1016/j.retram.2023.103432","url":null,"abstract":"<div><h3>Background</h3><p>Diffusing capacity<span> (DLCO) measurements are affected by hemoglobin. Two adjustment equations are used: Cotes (recommended by ATS/ERS) and Dinakara (used in the hematopoietic stem cell transplantation comorbidity index [HCT-CI]). It is unknown how these methods compare, and which is better from a prognostication standpoint.</span></p></div><div><h3>Study design</h3><p>This is a retrospective cohort of 1273 adult patients who underwent allogeneic HCT<span>, completed a pre-transplant DLCO and had a concurrent hemoglobin measurement. Non-relapse mortality was measured using competing risk analysis.</span></p></div><div><h3>Results</h3><p><span>Patients had normal spirometry (FEV</span>₁<span><span> 99.7% [IQR: 89.4–109.8%; FVC 100.1% [IQR: 91.0-109.6%] predicted), left ventricular ejection fraction (57.2[6.7]%) and right ventricular </span>systolic pressure (30.1[7.0] mmHg). Cotes-DLCO was 85.6% (IQR: 76.5-95.7%) and Dinakara-DLCO was 103.6% (IQR: 90.7-117.2%) predicted. For anemic patients (Hb&lt;10g/dL), Cotes-DLCO was 84.2% (IQR: 73.9–94.1%) while Dinakara-DLCO 111.0% (97.3–124.7%) predicted. Cotes-DLCO increased HCT-CI score for 323 (25.4%) and decreased for 4 (0.3%) patients. Cotes-DLCO was superior for predicting non-relapse mortality: for both mild (66-80% predicted, HR 1.55 [95%CI: 1.26-1.92, p &lt; 0.001]) and moderate (&lt;65% predicted, HR 2.11 [95%CI: 1.55-2.87, p&lt;0.001]) impairment. In contrast, for Dinakara-DLCO, only mild impairment (HR 1.69 [95%CI 1.26-2.27, p &lt; 0.001]) was associated with lower survival while moderate impairment was not (HR 1.44 [95%CI: 0.64-3.21, p = 0.4]). In multivariable analyses, after adjusting for demographics, hematologic variables, cardiac function and FEV</span>₁, Cotes-DLCO was predictive of overall survival at 1-year (OR 0.98 [95%CI: 0.97-1.00], p = 0.01), but Dinakara-DLCO was not (OR 1.00 [95%CI: 0.98-1.00], p = 0.20).</p></div><div><h3>Conclusion</h3><p>The ERS/ATS recommended Cotes method likely underestimates DLCO in patients with anemia, whereas the Dinakara (used in the HCT-CI score) overestimates DLCO. The Cotes method is superior to the Dinakara method score in predicting overall survival and relapse-free survival in patients undergoing allogeneic HCT.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 2","pages":"Article 103432"},"PeriodicalIF":4.1,"publicationDate":"2023-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138509199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performances of the H-score and the HLH-2004 score in the positive diagnosis of secondary hemophagocytic lymphohistiocytosis","authors":"Abida Fatma ,&nbsp;Ben Salah Raida ,&nbsp;Chaari Mourad ,&nbsp;Dammak Ikram ,&nbsp;Bahloul Zouheir ,&nbsp;Elleuch Henda","doi":"10.1016/j.retram.2023.103430","DOIUrl":"10.1016/j.retram.2023.103430","url":null,"abstract":"<div><p>Hemophagocytic lymphocytosis (HLH) is a rare clinical and biological entity that can be life-threatening. Early diagnosis can improve the overall prognosis of HLH.</p></div><div><h3>Objectives</h3><p>The aims of this study are to evaluate the performances of HLH-2004-score and H-score in identifying patients with secondary HLH and to determine an optimal H-score cut-off for our population.</p></div><div><h3>Methods</h3><p><span><span>A retrospective study that involved all patients, with images of hemophagocytosis in </span>myelograms<span> analyzed at the laboratory of hematology, followed at these departments: clinical-hematology, internal-medicine, infectious-diseases and </span></span>gastroenterology, University-Hospital \"Hédi-Chaker\", Sfax-Tunisia, (June2017-May2021). We identified two groups of patients: \"HLH\" and \"Not-HLH\". Then, for each patient, we calculated the HLH-2004-score and the H-score.</p></div><div><h3>Results</h3><p>Forty-two patients were included in this study. Twenty-five (60 %) belonging to group \"HLH\" and seventeen (40 %) to group \"Not-HLH\" with a mean age (38.72 vs. 39.82 years, p = 0.846) respectively. The study of the performances demonstrated that H-score had better performances. The best cut-off value of H-score for our population was 158.5, allowing a gain in sensitivity (from 92 % to 96 %) compared to the original study cut-off of 169.</p></div><div><h3>Conclusion</h3><p>Both H-score and HLH-2004-score showed excellent discriminative powers with better performances for H-score. The new H-score cut-off at 158.5 can be applied to our population.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 2","pages":"Article 103430"},"PeriodicalIF":4.1,"publicationDate":"2023-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135564566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}